

Sokhom Riri
09554860
12/19/2007
12/10/07

Amendments to the Specification

Please add the priority information paragraph to the specification by inserting the following new paragraph before the first line of the specification:

This application claims the benefit of §371 application of PCT/EP98/07521 filed 16 November 1997.

SR
12/10/07
Please replace the paragraph beginning at page 7, line ¹¹21 with the following amended paragraph:

The invention is illustrated herein, but not limited to, three specific mutations which are given as examples of proteolytically inactive DerP1. First, the enzymatic activity of DerP1 is abrogated by substituting a Cysteine residue in the active site for an alanine. This substitution occurs at Cys132→Ala132 of the pro-DerP1 protein sequence, and is set out in SEQ ID NO. 1. Second, the DerP1 allergen is recombinantly expressed and retained in its inactive pro-protein form by deletion of four amino acid residues at the linker region between the pro- and mature proteins. This deletion removes amino acid residues NAET (SEQ ID NO. 31) from the site 96-99 inclusive, from the Pro-DerP1 protein sequence. This sequence is set out in SEQ ID NO. 2. Third, enzymatic activity of DerP1 is abrogated by substituting a Histidine residue in the active site for an alanine. This substitution occurs at His268→Ala268 of the pro-DerP1 protein sequence, and is set out in SEQ ID NO. 3.

An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b). Please insert the attached abstract, following the claims.